Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

18.50 -0.07 (-0.40%)

Delayed Quote Updated: 12:26 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients ↗

February 15, 2022

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's...

Via Benzinga

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

February 15, 2022

From Legend Biotech

Via Business Wire

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

February 11, 2022

From Legend Biotech

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates ↗

February 01, 2022

After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 ↗

January 31, 2022

Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...

Via Benzinga

Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

December 30, 2021

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Corporation Announces Pricing of Public Offering

December 16, 2021

From Legend Biotech Corporation

Via Business Wire

18 Stocks Moving in Thursday's Pre-Market Session ↗

December 16, 2021

Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO...

Via Benzinga

46 Biggest Movers From Yesterday ↗

December 16, 2021

Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on...

Via Benzinga

36 Stocks Moving In Wednesday's Mid-Day Session ↗

December 15, 2021

Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 15, 2021

Gainers Gemini Therapeutics (NASDAQ:GMTX) shares moved upwards by 32.92% to $3.23 during Wednesday's pre-market session. The market value of their outstanding shares...

Via Benzinga

The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗

December 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 15, 2021

We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

20 Stocks Moving in Wednesday's Pre-Market Session ↗

December 15, 2021

Gainers Galera Therapeutics, Inc. (NASDAQ: GRTX) rose 17.7% to $3.18 in pre-market trading after BTIG upgraded the stock from Neutral to Buy and announced a $15 price target....

Via Benzinga

Legend Biotech Corporation Announces Proposed Public Offering

December 14, 2021

From Legend Biotech Corporation

Via Business Wire

JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma ↗

December 13, 2021

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), posted longer-term results from the Phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel...

Via Benzinga

Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma

December 13, 2021

From Legend Biotech

Via Business Wire

Why Are Legend Biotech Shares Gaining Today? ↗

December 07, 2021

Legend Biotech Corporation's (NASDAQ: LEGN) collaborating partner Janssen Pharmaceutical has submitted a marketing application to the Japanese...

Via Benzinga

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

December 07, 2021

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host Hybrid KOL Event Detailing CARTITUDE Data from the 63rd American Society of Hematology (ASH) Annual Meeting

December 07, 2021

From Legend Biotech

Via Business Wire

KILL Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

December 06, 2021

Via Business Wire

Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janssen

December 06, 2021

From Legend Biotech

Via Business Wire

80 Biggest Movers From Yesterday ↗

November 17, 2021

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG)...

Via Benzinga

53 Stocks Moving In Tuesday's Mid-Day Session ↗

November 16, 2021

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) jumped 65.7% to $1.0691 as the company reported a narrower Q3 loss. Progenity, Inc. (NASDAQ: PROG) shares climbed 35.5% to...

Via Benzinga

Legend Biotech Reports Third Quarter 2021 Financial Results and Recent Highlights

November 16, 2021

From Legend Biotech

Via Business Wire

Legend Biotech Showcases Updated and New Data from Comprehensive BCMA CAR-T, Cilta-Cel, Program and First Preclinical Results for Tri-specific CAR-T at 2021 ASH

November 04, 2021

From Legend Biotech Corporation

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates ↗

November 02, 2021

The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 02, 2021

Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo...

Via Benzinga

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.